Curevac Nv Stock Buy Hold or Sell Recommendation
| CVAC Stock | USD 2.44 0.13 5.06% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding CureVac NV is 'Hold'. Macroaxis provides CureVac NV buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CVAC positions. The advice algorithm takes into account all of CureVac NV's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting CureVac NV's buy or sell advice are summarized below:
Real Value 5.5 | Target Price 14.91 | Hype Value 2.42 | Market Value 2.44 | Naive Value 2.32 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell CureVac NV given historical horizon and risk tolerance towards CureVac NV. When Macroaxis issues a 'buy' or 'sell' recommendation for CureVac NV, the advice is generated through an automated system that utilizes algorithms and statistical models.
CureVac |
Execute CureVac NV Buy or Sell Advice
The CureVac recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on CureVac NV. Macroaxis does not own or have any residual interests in CureVac NV or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute CureVac NV's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
CureVac NV Trading Alerts and Improvement Suggestions
| CureVac NV generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 42.88 M. Net Loss for the year was (302.3 M) with loss before overhead, payroll, taxes, and interest of (91.55 M). | |
| CureVac NV currently holds about 540.87 M in cash with (273.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 45.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024 |
CureVac NV Returns Distribution Density
The distribution of CureVac NV's historical returns is an attempt to chart the uncertainty of CureVac NV's future price movements. The chart of the probability distribution of CureVac NV daily returns describes the distribution of returns around its average expected value. We use CureVac NV price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of CureVac NV returns is essential to provide solid investment advice for CureVac NV.
| Mean Return | -0.59 | Value At Risk | -5.06 | Potential Upside | 3.74 | Standard Deviation | 2.78 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of CureVac NV historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
CureVac Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as CureVac NV is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CureVac NV backward and forwards among themselves. CureVac NV's institutional investor refers to the entity that pools money to purchase CureVac NV's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Junked Platinum Investment Management Ltd | 2023-12-31 | 497.9 K | Eversept Partners, Llc | 2023-12-31 | 496.9 K | Norges Bank | 2023-12-31 | 308.7 K | Credit Suisse First Boston (csfb) | 2023-12-31 | 303.9 K | Adage Capital Partners Gp Llc | 2023-12-31 | 248.4 K | Geode Capital Management, Llc | 2023-12-31 | 202 K | Swiss National Bank | 2023-12-31 | 198.5 K | Susquehanna International Group, Llp | 2023-12-31 | 178.2 K | Ubs Group Ag | 2023-12-31 | 131.9 K | Citadel Advisors Llc | 2023-09-30 | 3.1 M | Ra Capital Management, Llc | 2023-12-31 | 2.7 M |
CureVac NV Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (3.2M) | (8.3M) | (227.5M) | (47.9M) | (61.8M) | (64.9M) | |
| Investments | 28.2M | (1.2M) | (127.9M) | (93.5M) | (61.7M) | (64.8M) | |
| Change In Cash | 9.3M | 1.3B | (511.1M) | (315.7M) | (69.5M) | (66.0M) | |
| Free Cash Flow | (99.2M) | 475.1M | (861.0M) | (379.4M) | (334.8M) | (351.6M) | |
| Depreciation | 7.2M | 10.7M | 15.7M | 23.7M | 17.8M | 14.5M | |
| Other Non Cash Items | 9.9M | 51.6M | (480.7M) | 57.2M | (5.5M) | (5.7M) | |
| Capital Expenditures | 12.2M | 47.4M | 127.9M | 93.2M | 61.5M | 65.4M | |
| Net Income | (100.1M) | (129.8M) | (412.5M) | (249.2M) | (302.3M) | (317.4M) | |
| End Period Cash Flow | 30.7M | 1.3B | 811.5M | 495.8M | 471.4M | 578.1M |
CureVac NV Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to CureVac NV or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that CureVac NV's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a CureVac stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.66 | |
β | Beta against NYSE Composite | 1.09 | |
σ | Overall volatility | 2.71 | |
Ir | Information ratio | -0.24 |
CureVac NV Volatility Alert
CureVac NV exhibits very low volatility with skewness of -0.49 and kurtosis of 0.97. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure CureVac NV's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact CureVac NV's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.CureVac NV Fundamentals Vs Peers
Comparing CureVac NV's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze CureVac NV's direct or indirect competition across all of the common fundamentals between CureVac NV and the related equities. This way, we can detect undervalued stocks with similar characteristics as CureVac NV or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of CureVac NV's fundamental indicators could also be used in its relative valuation, which is a method of valuing CureVac NV by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare CureVac NV to competition |
| Fundamentals | CureVac NV | Peer Average |
| Return On Equity | -0.49 | -0.31 |
| Return On Asset | -0.18 | -0.14 |
| Operating Margin | (3.33) % | (5.51) % |
| Current Valuation | 153.45 M | 16.62 B |
| Shares Outstanding | 223.92 M | 571.82 M |
| Shares Owned By Insiders | 45.43 % | 10.09 % |
| Shares Owned By Institutions | 23.80 % | 39.21 % |
| Number Of Shares Shorted | 5.01 M | 4.71 M |
| Price To Book | 1.01 X | 9.51 X |
| Price To Sales | 15.20 X | 11.42 X |
| Revenue | 42.88 M | 9.43 B |
| Gross Profit | (91.55 M) | 27.38 B |
| EBITDA | (242.09 M) | 3.9 B |
| Net Income | (302.3 M) | 570.98 M |
| Cash And Equivalents | 540.87 M | 2.7 B |
| Cash Per Share | 2.85 X | 5.01 X |
| Total Debt | 42.09 M | 5.32 B |
| Debt To Equity | 0.07 % | 48.70 % |
| Current Ratio | 3.61 X | 2.16 X |
| Book Value Per Share | 2.69 X | 1.93 K |
| Cash Flow From Operations | (273.37 M) | 971.22 M |
| Short Ratio | 6.80 X | 4.00 X |
| Earnings Per Share | (1.56) X | 3.12 X |
| Price To Earnings To Growth | 0.07 X | 4.89 X |
| Target Price | 13.16 | |
| Number Of Employees | 904 | 18.84 K |
| Beta | 2.51 | -0.15 |
| Market Capitalization | 575.48 M | 19.03 B |
| Total Asset | 860.47 M | 29.47 B |
| Retained Earnings | (1.31 B) | 9.33 B |
| Working Capital | 427.8 M | 1.48 B |
| Net Asset | 860.47 M |
CureVac NV Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as CureVac . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About CureVac NV Buy or Sell Advice
When is the right time to buy or sell CureVac NV? Buying financial instruments such as CureVac Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 176.3M | 46.2M | 53.2M | 69.9M | Total Assets | 1.2B | 860.5M | 989.5M | 833.0M |
Use Investing Ideas to Build Portfolios
In addition to having CureVac NV in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Most Shorted Equities Thematic Idea Now
Most Shorted Equities
Dynamically calculated list of top equities currently trending upward via a buy-out by investors. The Most Shorted Equities theme has 126 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Most Shorted Equities Theme or any other thematic opportunities.
| View All Next | Launch |
Check out CureVac NV Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.Note that the CureVac NV information on this page should be used as a complementary analysis to other CureVac NV's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for CureVac Stock analysis
When running CureVac NV's price analysis, check to measure CureVac NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CureVac NV is operating at the current time. Most of CureVac NV's value examination focuses on studying past and present price action to predict the probability of CureVac NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CureVac NV's price. Additionally, you may evaluate how the addition of CureVac NV to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |
Is CureVac NV's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.56) | Revenue Per Share 0.201 | Quarterly Revenue Growth 0.47 | Return On Assets (0.18) | Return On Equity (0.49) |
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.